Hemodialysis Treatment for Patients with Lithium Poisoning

Yu-Hsin Liu 1, Kai-Fan Tsai 2, Pai-Chin Hsu 2, Meng-Hsuan Hsieh 3, Jen-Fen Fu 4,5, I-Kuan Wang 6, Shou-Hsuan Liu 5,7, Cheng-Hao Weng 5,7, Wen-Hung Huang 5,7, Ching-Wei Hsu 5,7 and Tzung-Hai Yen 5,7,*

1 Department of Anaesthesiology, Chang Gung Memorial Hospital, Linkou, Taoyuan 333, Taiwan
2 Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833, Taiwan
3 Division of Nephrology, Department of Internal Medicine, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan 330, Taiwan
4 Department of Medical Research, Chang Gung Memorial Hospital, Linkou, Taoyuan 333, Taiwan
5 College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
6 Department of Nephrology, China Medical University Hospital, Taichung 406, Taiwan
7 Department of Nephrology, Clinical Poison Center, Chang Gung Memorial Hospital, Linkou, Taoyuan 333, Taiwan
* Correspondence: m19570@adm.cgmh.org.tw

Abstract: Background: Hemodialysis is often recommended to treat severe lithium poisoning. Nevertheless, the application rate of hemodialysis in patients with lithium poisoning is varied across different groups and the effect of hemodialysis is still undetermined. Therefore, this study aimed to analyze the hemodialysis rate of patients with lithium poisoning and to explore the clinical features of lithium-poisoned-patients treated or untreated with hemodialysis. Methods: Between 2001 and 2019, 36 patients treated at the Chang Gung Memorial Hospital for the management of lithium poisoning were stratified according to whether they were treated with hemodialysis (n = 7) or not (n = 29). Results: The patients were aged 50.7 ± 18.1 years. The poisoning patterns were acute on chronic lithium poisoning (61.1%), chronic (25.0%) and acute (13.9%). The precipitating factors of dehydration and infection were noted in 36.1% and 25.0% of patients, respectively. Bipolar disorder (72.2%), depressive disorder (27.8%) and psychotic disorder (11.1%) were the top three psychiatric comorbidities. The hemodialysis group not only had a lower Glasgow Coma Scale (GCS) score (p = 0.001) but also had a higher respiratory failure rate (p = 0.033), aspiration pneumonia rate (p = 0.033) and acute kidney injury network (AKIN) score (p = 0.002) than the non-hemodialysis group. Although none of the patients died of lithium poisoning, the hemodialysis group required more endotracheal intubation (p = 0.033), more intensive care unit admission (p = 0.033) and longer hospitalization (p = 0.007) than the non-hemodialysis group. Conclusion: The analytical results revealed zero mortality rate and low hemodialysis rate (1.9%). Compared with patients without hemodialysis, patients receiving hemodialysis suffered severer lithium-associated complications and needed a more intensive care unit admission and longer hospital stay.

Keywords: lithium; poisoning; psychiatric comorbidity; hemodialysis; acute kidney injury network score; mortality

1. Introduction

Lithium salt is a popular medication for bipolar disorder, but it has a narrow therapeutic index (0.6–1.2 mEq/L), and lithium toxicity may occur in cases of excessive intake or decreased excretion [1]. Lithium poisoning had a low mortality rate (Table 1) [1–19]. Although one study [7] reported a mortality rate of 12.5%, most studies have reported low mortality rates. One group [5] reported a zero mortality rate in their study, even though the studied patients had a mean blood lithium level of 3.43 mEq/L. The published mortality rates of patients with lithium poisoning were 0–12.5% before 2010. After 2011, the mortality...
rates dropped to 0–4.3%. Notably, when the sample size was larger than 100, the mortality rate was between 0.2% and 3.1%.

Table 1. Literature study on the outcomes of hemodialysis treatment for patients with lithium poisoning.

| Time   | Study                                | Area       | Sample Size | Peak Blood Lithium Level (mEq/L) | Hemodialysis Rate | Mortality Rate |
|--------|--------------------------------------|------------|-------------|----------------------------------|-------------------|---------------|
| 2022   | Current study                        | Taiwan     | 36          | 2.64                             | 1.9%              | 0%            |
| 2020   | Buckley et al. [18]                  | Australia  | 361         | 1.85                             | 2.5%              | 0.2%          |
| 2020   | Vodovar et al. [17]                  | France     | 128         | 3.2                              | 17.2%             | 3.1%          |
| 2020   | Hlaing et al. [16]                   | Australia  | 22          | 2.2                              | 13.6%             | 0%            |
| 2020   | Chan et al. [15]                     | Australia  | 242         | Not available                    | 1.6%              | 0.4%          |
| 2016   | Ott et al. [19]                      | Sweden     | 91          | Not available                    | 13.2%             | 4.3%          |
| 2016   | Vodovar et al. [14]                  | France     | 128         | 3.2                              | 17.2%             | 3.1%          |
| 2013   | Bretaudeau Deguigne et al. [13]      | France     | 59          | 3.65                             | 18.6%             | 3.4%          |
| 2012   | Lopez et al. [12]                    | Spain      | 65          | Not available                    | 21.0%             | 0%            |
| 2011   | Dennison et al. [11]                 | Ireland    | 47          | 2.62                             | 11.0%             | Not available |
| 2011   | Lee et al. [1]                       | Taiwan     | 21          | 2.54                             | 14.2%             | 0%            |
| 2010   | Offerman et al. [10]                 | USA        | 502         | 2.92                             | 13.7%             | 0.8%          |
| 2010   | Ghannoum et al. [9]                  | Canada     | 48          | 1.91                             | 14.5%             | 0%            |
| 2006   | Eyer et al. [8]                      | Germany    | 22          | 2.77                             | 40.9%             | 4.5%          |
| 2002   | Meltzer and Steinlauf [7]            | Israel     | 8           | Not available                    | Not available     | 12.5%         |
| 2000   | Bailey and McGuigan [6]              | Canada     | 205         | 2.10                             | Not available     | 1%            |
| 1993   | Jaeger et al. [5]                    | France     | 14          | 3.43                             | 21.4%             | 0%            |
| 1988   | Gadallah et al. [4]                  | United States | 55 | Not available                    | 9.1%              | 0%            |
| 1987   | Dyson et al. [3]                     | United Kingdom | 68 | Not available                    | 1.5%              | Not available |
| 1978   | Hansen and Amdisen [2]               | Denmark    | 23          | 3.2                              | 60.8%             | 8.6%          |

Hemodialysis is an important procedure for treating patients with severe lithium poisoning because it enhances lithium clearance. As shown in Table 1 [1–19], the published hemodialysis rates for lithium poisoning vary between 1.5% and 60.8%. However, the indications and benefits of hemodialysis remain controversial [20]. In 2015, the EXTRIP Workgroup published a systematic review of the indications for hemodialysis treatment for lithium poisoning [21]. According to these guidelines, hemodialysis is an ideal extracorporeal treatment for patients with lithium poisoning and the EXTRIP Workgroup supported the use of extracorporeal treatment for severe lithium poisoning. Nevertheless, clinical decisions on when to use extracorporeal treatment should consider the blood lithium level, renal function, pattern of lithium toxicity, patient condition and availability of hemodialysis services. Therefore, whether the indications for hemodialysis suit all types of lithium poisoning is still a matter of debate [17,18].

Lithium is not metabolized and is eliminated via the kidneys. Plasma lithium concentrations are sensitive to physiological factors that influence kidney function, for instance age, fluid status, hemodynamics and sodium balance [22,23]. Therefore, drug interactions do not include biotransformation through enzyme systems such as cytochrome P450. On the other hand, the drug interactions occur through the direct effect of other medicines upon renal function and glomerular filtration rate. Thiazide, loop diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and non-steroidal anti-inflammatory drugs were known for their influence on increasing plasma lithium level. Some other medicines such as antidepressants, antipsychotics, antiepileptic drugs and non-depolarizing neuromuscular blockers do not alter the lithium serum level, but may cause adverse neurotoxicity.

Hemodialysis is often recommended to treat severe lithium poisoning. Nevertheless, the application rate of hemodialysis in patients with lithium poisoning is varied across different groups and the effect of hemodialysis is still undetermined. Given the recommendation by the EXTRIP Workgroup of the use of hemodialysis treatment for severe lithium poisoning, we hypothesized that hemodialysis treatment could exert clinical improvement for patients with severe lithium poisoning by providing rapid extracorporeal removal of lithium. Therefore, the objective of this study was to analyze the hemodialysis rate of patients with lithium poisoning and to explore the clinical features of lithium-poisoned patients treated or untreated with hemodialysis.
2. Materials and Methods

2.1. Patients

Between 2001 and 2019, 36 patients were treated at Chang Gung Memorial Hospital for the management of lithium poisoning. Medical records, including emergency department records, admission, progress and discharge records, nursing records, psychiatric consultation records and outpatient clinic records, were reviewed. Demographic data, such as age, sex, marital status and employment status, were collected, along with the patients’ medical and psychiatric comorbidities. Information on lithium therapy, such as the dose and duration, was also obtained. The patterns of poisoning, precipitating factors and clinical findings were studied. Clinical, physical and laboratory findings, including complete blood counts, biochemistry and lithium levels, were analyzed. Clinical outcomes were assessed and treatment modalities were evaluated.

2.2. Patient Group

Patients with lithium poisoning were stratified according to whether they were treated with hemodialysis (\( n = 7 \)) or not (\( n = 29 \)).

2.3. Inclusion and Exclusion Criteria

All patients aged \( \geq 18 \) years with confirmed lithium poisoning were recruited for the analysis. Patients aged < 18 years were excluded from the study. Patients were also excluded if they did not have detectable lithium levels in the blood despite suspicion of lithium poisoning.

2.4. Diagnosis of Lithium Poisoning

Lithium poisoning was diagnosed on the basis of exposure history, clinical findings and physical examinations, and the poisoning was confirmed by a blood lithium test. Blood lithium levels were determined using a spectrophotometric method. The therapeutic level was 0.6–1.2 mEq/L, warning level was 1.2–1.5 mEq/L and toxic level was >1.5 mEq/L.

2.5. Clinical Event Definitions

The clinical patterns of lithium poisoning were defined as: acute poisoning, arising in patients not previously receiving lithium; acute-on-chronic poisoning, resulting from acute ingestion during lithium therapy; and chronic poisoning, therapeutic misadventure due to insufficient monitoring, unsuitably high target levels or intercurrent diseases [24]. The Glasgow Coma Scale (GCS) was scored according to ocular, verbal and motor responses. The lowest score was 3 (deep coma), whereas the highest score was 15 (completely awake). Acute kidney injury was scored according to the Acute Kidney Injury Network (AKIN) criteria [25], which defines and categorizes the severity of acute kidney injury in three stages using serum creatinine and urine output.

2.6. Detoxification Protocol

The goal of detoxification therapy was to ascertain lithium concentration < 1 mEq/L stably within 6 h from hemodialysis. Patients were treated with large amounts of normal saline, as fluid resuscitation is crucial in the initial management of lithium poisoning. The protocol did not include forced emesis, polyethylene glycol enema or sodium polystyrene sulfonate resin. The decision of performing hemodialysis depended on serial lithium levels, renal function and clinical condition.

2.7. Indications for Hemodialysis Treatment

The indications for hemodialysis included [24] (1) any patient with a lithium level > 6 mEq/L; (2) any patient on chronic lithium therapy with a lithium level > 4 mEq/L; (3) any patient with serum lithium levels ranging from 2.5 to 4.0 mEq/L, with severe neurologic symptoms, renal failure or hemodynamic instability; (4) any patient with a serum lithium
level < 2.5 mEq/L with end-stage kidney disease; and (5) any patient whose lithium levels rose after admission or failed to reach a lithium level < 1 mEq/L in 30 h.

2.8. Hemodialysis Procedure

The procedure was performed for 4 h using a femoral vein catheter [1]. The blood and dialysate flow rates were 200 and 500 mL/min, respectively. Zero ultrafiltration volume was prescribed to avoid fluid removal. Hemodialysis was conducted using hollow-fiber dialyzers fitted with modified cellulose membranes. The dialysate used had a standard ionic composition with bicarbonate buffer and a standard reverse osmosis system technique was employed for water purification.

2.9. Statistical Analysis

All data were tested for the normality of distribution and equality of standard deviations before analysis. Continuous variables are expressed as mean and standard deviations and categorical variables are presented as numbers and percentages in parentheses. Student’s t-test was used to analyze quantitative variables and the chi-square or Fisher’s exact test was used for categorical variables. A p-value of less than 0.05 was selected as the significance threshold to reject the null hypothesis. All analyses were performed using the IBM SPSS Statistics version 20.0 (IBM Corp., New York, NY, USA).

3. Results

Table 2 shows the baseline characteristics of patients with lithium poisoning, stratified according to whether they were treated with hemodialysis or not. Four patients received one treatment of hemodialysis, and the other three patients underwent hemodialysis treatment twice. The patients had an average age of 50.7 ± 18.1 years and 44% of the patients were male. Hypertension and diabetes mellitus were noted in 30.6% and 22.2% of patients, respectively. Most of the poisonings were acute on chronic (61.1%), followed by chronic (25.0%) and acute (13.9%). The mean daily dose of lithium was 675.0 ± 260.8 mg, and the mean duration of lithium therapy was 42.6 ± 69.1 months. Regarding the precipitating factors for lithium poisoning, dehydration and infection were found in 36.1% and 25.0% of patients, respectively. There were no significant differences in the baseline data between both groups.

Table 2. Baseline characteristics of patients with lithium poisoning, stratified according to whether they were treated with hemodialysis or not (n = 36).

| Variables                          | Hemodialysis Patients (n = 7) | Non-Hemodialysis Patients (n = 29) | All Patients (n = 36) | p-Value |
|-----------------------------------|------------------------------|------------------------------------|---------------------|--------|
| Age, year                         | 48.7 ± 15.7                  | 51.2 ± 18.8                        | 50.7 ± 18.1         | 0.766  |
| Male, n (%)                       | 2 (28.6)                     | 14 (48.3)                          | 16 (44.4)           | 0.426  |
| Body mass index, kg/m²            | 24.2 ± 2.7                   | 26.2 ± 3.9                         | 25.7 ± 3.7          | 0.297  |
| Unemployed, n (%)                 | 6 (85.7)                     | 21 (72.4)                          | 27 (75.0)           | 0.652  |
| Living alone, n (%)               | 0 (0)                        | 3 (10.3)                           | 3 (8.3)             | 1.000  |
| Pattern of poisoning, n (%)       | 0 (0)                        | 5 (17.2)                           | 5 (13.9)            | 0.291  |
| Acute, n (%)                      | 0 (0)                        | 16 (55.2)                          | 22 (61.1)           |        |
| Chronic, n (%)                    | 1 (14.3)                     | 8 (27.6)                           | 9 (25.0)            |        |
| Lithium dose, mg/day              | 480.0 ± 268.3                | 732.4 ± 236.5                      | 675.0 ± 260.8       | 0.055  |
| Duration of lithium therapy, month| 6.4 ± 8.2                    | 49.1 ± 73.2                        | 42.6 ± 69.1         | 0.208  |
| Precipitating dehydration, n (%)  | 2 (28.6)                     | 11 (37.9)                          | 13 (36.1)           | 1.000  |
| Precipitating infection, n (%)    | 1 (14.3)                     | 8 (27.6)                           | 9 (25.0)            | 0.652  |
| Hypertension, n (%)               | 3 (42.9)                     | 8 (27.6)                           | 11 (30.6)           | 0.650  |
| Diabetes mellitus, n (%)          | 2 (28.6)                     | 6 (20.7)                           | 8 (22.2)            | 0.639  |
| Cardiovascular disease, n (%)     | 0 (0)                        | 2 (6.9)                            | 2 (5.6)             | 1.000  |
| Cerebrovascular, n (%)            | 0 (0)                        | 1 (3.4)                            | 1 (2.8)             | 1.000  |
| Thyroid disease, n (%)            | 1 (14.3)                     | 0 (0)                              | 1 (2.8)             | 0.194  |
| Hepatic disease, n (%)            | 0 (0)                        | 3 (10.3)                           | 3 (8.3)             | 1.000  |
| Kidney disease, n (%)             | 0 (0)                        | 3 (10.3)                           | 3 (8.3)             | 1.000  |
| Neurological disease, n (%)       | 2 (28.6)                     | 2 (6.9)                            | 4 (11.1)            | 0.163  |
| Gastrointestinal disease, n (%)   | 0 (0)                        | 2 (6.9)                            | 2 (5.6)             | 1.000  |
| Malignancy, n (%)                 | 0 (0)                        | 1 (3.4)                            | 1 (2.8)             | 1.000  |
| Smoking habit, n (%)              | 1 (14.3)                     | 10 (34.5)                          | 11 (30.6)           | 0.400  |
| Alcohol consumption, n (%)        | 1 (14.3)                     | 8 (27.6)                           | 9 (25)              | 0.625  |
| Medications                       |                              |                                    |                     |        |
| Thiazide, n (%)                   | 0 (0)                        | 1 (3.4)                            | 1 (2.8)             | 1.000  |
| Loop diuretics, n (%)             | 0 (0)                        | 3 (10.3)                           | 3 (8.3)             | 1.000  |
| Angiotensin-converting enzyme inhibitors, n (%) | 0 (0)             | 0 (0)                              | 0 (0)               | 1.000  |
| Angiotensin receptor blockers, n (%) | 2 (28.6)                   | 2 (6.9)                            | 4 (11.1)            | 0.163  |
| Non-steroidal anti-inflammatory drugs, n (%) | 1 (14.3)                     | 0 (0)                              | 1 (2.8)             | 0.194  |
As shown in Table 3, bipolar disorders (72.2%), depressive disorders (27.8%) and psychotic disorders (11.1%) were the top three psychiatric comorbidities among patients with lithium poisoning. There were no significant differences in psychiatric comorbidities between the groups.

Table 3. Psychiatric comorbidities of patients with lithium poisoning, stratified according to whether they were treated with hemodialysis or not (n = 36).

| Psychiatric Diagnosis        | Hemodialysis Patient (n = 7) | Non-Hemodialysis Patients (n = 29) | All Patients (n = 36) | p-Value |
|------------------------------|------------------------------|-----------------------------------|----------------------|---------|
| Adjustment disorder, n (%)   | 0 (0)                        | 0 (0)                             | 0 (0)                | 1.000   |
| Depressive disorder, n (%)   | 2 (28.6)                     | 8 (27.6)                          | 10 (27.8)            | 1.000   |
| Bipolar disorder, n (%)      | 5 (71.4)                     | 21 (72.4)                         | 26 (72.2)            | 1.000   |
| Psychotic disorder, n (%)    | 1 (14.3)                     | 3 (10.3)                          | 4 (11.1)             | 1.000   |
| Substance abuse, n (%)       | 0 (0)                        | 0 (0)                             | 0 (0)                | 1.000   |
| Alcoholic, n (%)             | 0 (0)                        | 3 (10.3)                          | 3 (8.3)              | 1.000   |
| Delirium or dementia, n (%)  | 0 (0)                        | 1 (3.4)                           | 1 (2.8)              | 1.000   |

Neurological complications were the predominant symptoms: 33.3% of patients had muscle tremors, 30.6% had drowsiness and 19.4% had dizziness, ataxia or muscle weakness (Table 4). The hemodialysis group not only had a lower GCS score (p = 0.001), but also had a higher respiratory failure rate (p = 0.033), higher aspiration pneumonia rate (p = 0.033) and higher AKIN score (p = 0.002) than the non-hemodialysis group. Three patients suffered renal diabetes insipidus, with average urine outputs and specific gravity of 6880 mL, 4750 mL and 6900 mL urine per day, as well as 1.005, 1.005 and 1.003, respectively.

Table 4. Clinical manifestations of patients with lithium poisoning, stratified according to whether they were treated with hemodialysis or not (n = 36).

| Variables                  | Hemodialysis Patient (n = 7) | Non-Hemodialysis Patients (n = 29) | All Patients (n = 36) | p-Value |
|----------------------------|------------------------------|-----------------------------------|----------------------|---------|
| Body temperature, °C       | 37.0 ± 0.7                   | 36.8 ± 0.6                        | 36.9 ± 0.6           | 0.450   |
| Heart rate, per minute     | 100.0 ± 30.8                 | 79.4 ± 19.6                       | 83.4 ± 23.2          | 0.033 * |
| Respiratory rate, per minute| 19.0 ± 2.6                   | 18.8 ± 1.9                        | 18.8 ± 2.0           | 0.813   |
| Systolic blood pressure, mmHg | 126.0 ± 14.9             | 126.7 ± 26.5                      | 126.6 ± 24.5         | 0.950   |
| Diastolic blood pressure, mmHg | 71.4 ± 14.3             | 76.3 ± 15.3                       | 75.4 ± 15.0          | 0.448   |
| Glasgow Coma Scale score   | 10.9 ± 4.3                   | 14.2 ± 1.3                        | 13.6 ± 2.5           | 0.001 **|
| Neurological complications |                             |                                   |                      |         |
| Drowsiness, n (%)          | 4 (57.1)                     | 7 (24.1)                          | 11 (30.6)            | 0.167   |
| Slurred speech, n (%)      | 1 (14.3)                     | 4 (13.8)                          | 5 (13.9)             | 1.000   |
| Dizziness, n (%)           | 1 (14.3)                     | 6 (20.7)                          | 7 (19.4)             | 1.000   |
| Ataxia, n (%)              | 1 (14.3)                     | 6 (20.7)                          | 7 (19.4)             | 1.000   |
| Muscle twitching, n (%)    | 2 (28.6)                     | 1 (3.4)                           | 3 (8.3)              | 0.090   |
| Muscle weakness, n (%)     | 1 (14.3)                     | 6 (20.7)                          | 7 (19.4)             | 1.000   |
| Rigidity, n (%)            | 2 (28.6)                     | 4 (13.8)                          | 6 (16.7)             | 0.573   |
| Tremor, n (%)              | 3 (42.9)                     | 9 (31.0)                          | 12 (33.3)            | 0.664   |
| Cardiovascular complications|                             |                                   |                      |         |
| Hypertension, n (%)        | 0 (0)                        | 1 (3.4)                           | 1 (2.8)              | 1.000   |
| Hypotension, n (%)         | 0 (0)                        | 1 (3.4)                           | 1 (2.8)              | 1.000   |
| Sinus tachycardia, n (%)   | 1 (14.3)                     | 2 (6.9)                           | 3 (8.3)              | 0.488   |
| Sinus brady cardia, n (%)  | 1 (14.3)                     | 4 (13.8)                          | 5 (13.9)             | 1.000   |
| Corrected QT interval      |                             |                                   |                      |         |
| prolongation, n (%)        | 2 (28.6)                     | 1 (3.4)                           | 3 (8.3)              | 0.090   |
| Respiratory complication   |                             |                                   |                      |         |
| Respiratory failure, n (%) | 2 (28.6)                     | 0 (0)                             | 2 (5.6)              | 0.033 * |
| Aspiration pneumonia, n (%)| 2 (28.6)                     | 0 (0)                             | 2 (5.6)              | 0.033 * |
| Gastrointestinal complications |                             |                                   |                      |         |
| Nausea and vomiting, n (%) | 2 (28.6)                     | 10 (34.5)                         | 12 (33.3)            | 1.000   |
| Anorexia, n (%)            | 0 (0)                        | 7 (24.1)                          | 7 (19.4)             | 0.303   |
| Diarrhea, n (%)            | 4 (57.1)                     | 6 (20.7)                          | 10 (27.8)            | 0.076   |
| AKIN score                 |                             |                                   |                      |         |
| Class 1                    | 0 (0)                        | 10 (34.5)                         | 10 (27.8)            | 0.002 **|
| Class 2                    | 0 (0)                        | 2 (6.9)                           | 2 (5.6)              |         |
| Class 3                    | 4 (57.1)                     | 1 (3.4)                           | 5 (13.9)             |         |
| Total                      | 4 (57.1)                     | 13 (44.8)                         | 17 (47.2)            |         |
| Diabetes insipidus, n (%)  | 1 (14.3)                     | 2 (6.9)                           | 3 (8.3)              | 0.488   |

Note: AKIN acute kidney injury network; * p < 0.05, ** p < 0.01.
The hemodialysis group had higher peak serum creatinine levels than the non-hemodialysis group \((p = 0.002, \text{Table 5})\). In addition, the hemodialysis group also had higher blood lithium levels than the non-hemodialysis group \((3.2 \pm 12 \text{ versus } 2.5 \pm 1.0)\), but this was not statistically significant \((p = 0.135)\). There was no evidence of new onset diabetes and no changes in diabetic treatment after lithium poisoning.

Table 5. Laboratory data of patients with lithium poisoning, stratified according to whether they were treated with hemodialysis or not \((n = 36)\).

| Variables                                      | Hemodialysis Patient \((n = 7)\) | Non-Hemodialysis Patients \((n = 29)\) | All Patients \((n = 36)\) | \(p\)-Value |
|------------------------------------------------|----------------------------------|----------------------------------------|---------------------------|------------|
| White blood cell count, 1000/µL                | 12,957.1 ± 4919.6                | 11,427.6 ± 5472.8                     | 11,725.0 ± 5337.3        | 0.504      |
| Neutrophils, %                                 | 75.7 ± 11.6                      | 73.9 ± 12.1                            | 74.3 ± 11.9              | 0.728      |
| Hemoglobin, g/dL                               | 12.0 ± 1.4                       | 12.5 ± 1.2                             | 12.4 ± 1.2               | 0.347      |
| Mean corpuscular volume, fl                    | 89.4 ± 4.4                       | 92.4 ± 5.1                             | 91.8 ± 5.1               | 0.162      |
| Red cell distribution width, %                 | 13.8 ± 1.2                       | 13.2 ± 0.6                             | 13.3 ± 0.8               | 0.052      |
| Platelet count, 1000/µL                        | 277.1 ± 77.9                     | 246.8 ± 76.9                           | 252.7 ± 77.0             | 0.357      |
| Alanine aminotransferase, U/L                  | 53.1 ± 73.6                      | 33.7 ± 41.6                            | 38.0 ± 49.5              | 0.368      |
| Random glucose, mg/dL                          | 141.0 ± 77.2                     | 123.9 ± 39.6                           | 127.8 ± 48.8             | 0.506      |
| Random glucose, mg/dL (after discharge)        | 160.0 ± 71.2                     | 152.0 ± 38.1                           | 155.1 ± 47.9             | 0.832      |
| Blood urea nitrogen, mg/dL                     | 39.6 ± 27.5                      | 24.5 ± 17.7                            | 27.3 ± 20.1              | 0.134      |
| Creatinine, mg/dL                              | 3.6 ± 3.0                        | 1.5 ± 0.8                              | 1.9 ± 1.7                | 0.002 **   |
| Potassium, mEq/L                               | 3.7 ± 0.9                        | 4.1 ± 0.6                              | 4.0 ± 0.7                | 0.155      |
| Sodium, mEq/L                                  | 137.0 ± 4.7                      | 139.0 ± 4.0                            | 138.6 ± 4.1              | 0.248      |
| Calcium                                        | 8.8 ± 0.4                        | 9.1 ± 1.0                              | 9.0 ± 0.8                | 0.439      |
| Thyroid stimulating hormone (lithium, arrival), mEq/L | 2.3 ± 2.4                      | 2.9 ± 1.7                              | 2.8 ± 1.8                | 0.554      |
| Lithium (after hemodialysis), mEq/L             | 3.2 ± 12                         | 2.5 ± 1.0                              | 2.6 ± 1.1                | 0.135      |
| Interval between first and second lithium test, hour | 38.4 ± 25.6                  | 78.2 ± 100.4                           | 70.5 ± 91.8              | 0.311      |

Note: ** \(p < 0.01\).

As shown in Table 6, none of the patients died of lithium poisoning. The hemodialysis group required more endotracheal intubation and mechanical ventilation \((p = 0.033)\), more intensive care unit admission \((p = 0.033)\) and longer hospitalization \((p = 0.007)\) than the non-hemodialysis group.

Table 6. Outcomes of patients with lithium poisoning, stratified according to whether they were treated with hemodialysis or not \((n = 36)\).

| Variables                                      | Hemodialysis Patient \((n = 7)\) | Non-Hemodialysis Patients \((n = 29)\) | All Patient \((n = 36)\) | \(p\)-Value |
|------------------------------------------------|----------------------------------|----------------------------------------|---------------------------|------------|
| Hospitalization duration, day                  | 16.9 ± 8.9                       | 8.1 ± 6.7                              | 9.9 ± 7.9                | 0.007 **   |
| Intensive care unit admission, n (%)           | 2 (28.6)                         | 0 (0)                                  | 2 (5.6)                  | 0.033 *    |
| Endotracheal intubation and mechanical ventilation, n (%) | 2 (28.6)                      | 0 (0)                                  | 2 (5.6)                  | 0.033 *    |
| Mortality, n (%)                               | 0 (0)                            | 0 (0)                                  | 0 (0)                    | 1.000      |

Note: * \(p < 0.05\), ** \(p < 0.01\).

4. Discussion

The hemodialysis group had a higher AKIN score than the non-hemodialysis group \((p = 0.002; \text{Table 5})\). Acute kidney injury (AKI) is common in patients with lithium poisoning. According to a systematic review by the EXTRIP Workgroup [21], acute kidney injury occurred in 32.3% of patients with acute and acute-on-chronic lithium poisoning and 58.3% of patients with chronic lithium poisoning. In this study, acute kidney injury was observed in 47.3% of the patients (Table 5). The pathophysiological mechanism underlying the effects of lithium on decreased glomerular filtration rate remains poorly understood. Once lithium is ingested, it is distributed throughout the body within a few hours. Lithium is not metabolized and is excreted entirely in urine. Approximately, 80% of lithium is filtered by the glomerulus and is reabsorbed: 60% by the proximal tubule and 20% by
Two patients (5.6%; Table 6) experienced respiratory failure and required mechanical ventilator support. Both the patients had acute-on-chronic poisoning. Both patients had a low Glasgow Coma Scale (6 and 4, respectively) on hospital arrival. One patient showed labored breath and the other experienced apnea during hemodialysis. Aspiration pneumonia was found in two cases. According to a literature analysis, the mechanical ventilation rates of patients with lithium poisoning ranged between 1.7% and 13.6% [8,10,13]. Respiratory failure is an uncommon manifestation of lithium poisoning; however, it can be induced by consciousness disturbance, severe neurological symptoms, aspiration pneumonia or acute respiratory distress syndrome (ARDS). Five cases of lithium-associated ARDS have been reported in the literature [27–30]. These five patients had blood lithium levels of 3.3–4.9 mEq/L. Other causes of ARDS such as cardiogenic pulmonary edema, neurogenic pulmonary edema, pulmonary embolism, diffuse pneumonia, toxin injury and dialysis-induced hypoxia were excluded. According to Bloomfield and Young [31], lithium can enhance neutrophil degranulation and induce inflammation in the pulmonary parenchyma in animal models. In addition, Weiner et al. [32] stated that lithium can depress the brain respiratory drive.

Most patients had psychiatric comorbidities such as bipolar disorder (72.2%) or depressive disorder (27.8%, Table 3). Four patients had psychotic disorders, three patients had alcoholism and one patient had dementia. Lithium therapy is indicated mainly in patients with bipolar disorder and sometimes in depressed patients [33,34]. The mechanisms of action of lithium therapy are only partially understood. According to Alda [35], lithium may reduce excessive neuronal activity and contribute to the stabilization of neuronal activity, stress resilience, neuronal or synaptic plasticity and regulation of chronobiological function. In other studies [12,16], schizophrenia and schizoaffective disorder were psychiatric comorbidities that may also use lithium as an augmentation of antipsychotic medication, and these patients could also experience lithium poisoning. Alcohol abuse is another possible psychiatric comorbidity reported by Lopez et al. [12]. Therefore, patients with psychiatric comorbidities may have access to lithium and, at the same time, they have a higher risk of impulse usage or overdosing themselves with medication. Therefore, understanding psychiatric comorbidities may help clinicians evaluate their clinical condition and prevent the incidence of lithium poisoning.

As shown in Table 2, acute chronic poisoning (61.1%) was the primary cause of poisoning. Moreover, acute chronic poisoning comprised 85.7% of the cases in the hemodialysis group. In the studies that analyzed three types of poisoning patterns [1,3,6–8,10,18,19], acute-on-chronic patterns ranged from 24.7% to 84.9%. In studies that analyzed acute on chronic as the predominant pattern [1,3,5,6,12,17], the proportions of acute-on-chronic poisoning were 47.6–84.9%. Additionally, higher blood lithium levels have been reported in patients with acute-on-chronic poisoning than in those with chronic poisoning [18]. This study showed a zero-mortality rate and low hemodialysis rate (1.9%). The favorable outcome was similar to data from other international poison centers. As shown in Table 1 [1–19], the published mortality and hemodialysis rates of patients with lithium poisoning were 0–12.5% and 1.5–60.8%, respectively. Most published lithium studies are from Western countries, but a few studies are from Asian countries. Accessibility to medical care and hemodialysis intervention is higher in Western countries than in Asian countries. Therefore, it would be helpful for clinicians to understand the outcomes of patients with lithium poisoning by collecting epidemiological data from Asian countries. Finally, this study was limited by its retrospective design, small patient population, considerable variation in the age of the patient population and the small number of hemodialysis procedures performed. Therefore, further studies are warranted.
5. Conclusions

The analytical results revealed a zero-mortality rate and low hemodialysis rate (1.9%). The poisoning patterns were acute on chronic (61.1%), followed by chronic (25.0%) and acute (13.9%). Bipolar disorders (72.2%), depressive disorders (27.8%) and psychotic disorders (11.1%) were the top three psychiatric comorbidities. Importantly, patients receiving hemodialysis had lower GCS scores, higher AKIN scores and higher rates of respiratory failure, and therefore required more intensive care unit admission ($p = 0.033$) and longer hospitalization periods than patients without hemodialysis.

**Author Contributions:** Data collection and manuscript writing, Y.-H.L.; Data analysis, K.-F.T., P.-C.H., M.-H.H., J.-F.F. and I.-K.W.; Patient care and management, S.-H.L., C.-H.W., W.-H.H., C.-W.H. and T.-H.Y.; Study design and supervision, T.-H.Y. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was funded by Chang Gung Memorial Hospital, grant number CORPG3M0201 and CORPG3K0193.

**Institutional Review Board Statement:** This study complied with the Declaration of Helsinki and the study was approved by the Medical Ethics Committee of the Chang Gung Memorial Hospital. The Institutional Review Board number was 201800245B0C102.

**Informed Consent Statement:** As this was a retrospective study based on the assessment of existing data, the committee waived the requirement for informed consent from the patients. All personal data were only available to investigators and were secured by delinking the recognition information from the main dataset.

**Data Availability Statement:** The datasets used and analyzed for this study are available from the corresponding author upon request.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Lee, Y.C.; Lin, J.L.; Lee, S.Y.; Hsu, C.W.; Weng, C.H.; Chen, Y.H.; Yang, C.W.; Yen, T.H. Outcome of patients with lithium poisoning at a far-east poison center. *Hum. Exp. Toxicol.* 2011, 30, 528–534. [CrossRef]
2. Hansen, H.E.; Amdisen, A. Lithium intoxication (Report of 23 cases and review of 100 cases from the literature). QJM Int. J. Med. 1978, 47, 123–144.
3. Dyson, E.H.; Simpson, D.; Prescott, L.F.; Proudfoot, A.T. Self-poisoning and therapeutic intoxication with lithium. *Hum. Toxicol.* 1987, 6, 325–329. [CrossRef]
4. Gadallah, M.F.; Feinstein, E.I.; Massry, S.G. Lithium intoxication: Clinical course and therapeutic considerations. * Miner Electrolyte Metab.* 1988, 14, 146–149. [PubMed]
5. Jaeger, A.; Sauder, P.; Koppferschmitt, J.; Tritsch, L.; Flesch, F. When should dialysis be performed in lithium poisoning? A kinetic study in 14 cases of lithium poisoning. *J. Toxicol. Clin. Toxicol.* 1993, 31, 429–447. [CrossRef] [PubMed]
6. Bailey, B.; McGuigan, M. Lithium poisoning from a poison control center perspective. *Ther. Drug Monit.* 2000, 22, 650–655. [CrossRef]
7. Meltzer, E.; Steinlauf, S. The clinical manifestations of lithium intoxication. *Isr. Med. Assoc. J.* 2002, 4, 265–267.
8. Eyer, F.; Pfab, R.; Felgenhauer, N.; Lutz, J.; Heemann, U.; Steimer, W.; Zondler, S.; Fichtl, B.; Zilker, T. Lithium poisoning: Pharmacokinetics and clearance during different therapeutic measures. *J. Clin. Psychopharmacol.* 2006, 26, 325–330. [CrossRef]
9. Ghannoum, M.; Lavergne, V.; Yue, C.S.; Ayoub, P.; Perreault, M.M.; Roy, L. Successful treatment of lithium toxicity with sodium polystyrene sulfonate: A retrospective cohort study. *Clin. Toxicol.* 2010, 48, 34–41. [CrossRef]
10. Offerman, S.R.; Alsop, J.A.; Lee, J.; Holmes, J.F. Hospitalized lithium overdose cases reported to the california poison control system. *Clin. Toxicol.* 2010, 48, 443–448. [CrossRef]
11. Dennison, U.; Clarkson, M.; O’Mullane, J.; Cassidy, E.M. Cassidy. The incidence and clinical correlates of lithium toxicity: A retrospective review. *Ir. J. Med. Sci.* 2011, 180, 661–665. [CrossRef]
12. Lopez, J.C.; Perez, X.; Labad, J.; Esteve, F.; Manez, R.; Javierre, C. Higher requirements of dialysis in severe lithium intoxication. *Hemodial. Int.* 2012, 16, 407–413. [CrossRef]
13. Deguigne, M.B.; Hamel, J.F.; Boels, D.; Harry, P. Lithium poisoning: The value of early digestive tract decontamination. *Clin. Toxicol.* 2013, 51, 243–248. [CrossRef] [PubMed]
14. Vodovar, D.; El Balkhi, S.; Curis, E.; Deyé, N.; Mégarbane, B. Lithium poisoning in the intensive care unit: Predictive factors of severity and indications for extracorporeal toxin removal to improve outcome. *Clin. Toxicol.* 2016, 54, 615–623. [CrossRef]
15. Chan, B.S.; Cheng, S.; Isoardi, K.Z.; Chiew, A.; Siu, W.; Shulruf, B.; Vecellio, E.; Buckley, N.A. Effect of age on the severity of chronic lithium poisoning. *Clin. Toxicol.* 2020, 58, 1023–1027. [CrossRef] [PubMed]

16. Hlaing, P.M.; Isoardi, K.Z.; Page, C.B.; Pillans, A.P. Neurotoxicity in chronic lithium poisoning. *Intern. Med. J.* 2020, 50, 1023–1027. [CrossRef] [PubMed]

17. Vodovar, D.; Beaune, S.; Langrand, J.; Vicaut, E.; Labat, L.; Mégarbane, B. Assessment of extracorporeal treatments in poisoning criteria for the decision of extracorporeal toxin removal in lithium poisoning. *Br. J. Clin. Pharmacol.* 2020, 86, 560–568. [CrossRef] [PubMed]

18. Buckley, N.A.; Cheng, S.; Isoardi, K.; Chiew, A.L.; Siu, W.; Vecellio, E.; Chan, B.S. Haemodialysis for lithium poisoning: Translating extrip recommendations into practical guidelines. *Br. J. Clin. Pharmacol.* 2020, 86, 999–1006. [CrossRef] [PubMed]

19. Ott, M.; Stegmayr, B.; Renberg, E.S.; Werneke, U. Lithium intoxication: Incidence, clinical course and renal function—A population-based retrospective cohort study. *J. Psychopharmacol.* 2016, 30, 1008–1019. [CrossRef] [PubMed]

20. Haussmann, R.; Bauer, M.; von Bonin, S.; Grof, P.; Lewitzka, U. Treatment of lithium intoxication: Facing the need for evidence. *Int. J. Bipolar. Disord.* 2015, 3, 23. [CrossRef] [PubMed]

21. Decker, B.S.; Goldfarb, D.S.; Dargan, P.I.; Friesen, M.; Gosselin, S.; Hoffman, R.S.; Lavergne, V.; Nolin, T.D.; Ghannoum, M.; Workgroup, O.B.O.T.E. Extracorporeal treatment for lithium poisoning: Systematic review and recommendations from the extrip workgroup. *Clin. J. Am. Soc. Nephrol.* 2015, 10, 875–887. [CrossRef]

22. Finley, P.R. Drug interactions with lithium: An update. *Clin. Pharmacokinet.* 2016, 55, 925–941. [CrossRef] [PubMed]

23. Medi, B.; Stojanović, M.; Stimec, B.V.; Divac, N.; Vujović, K.S.; Stojanović, R.; Čolović, M.; Krstić, D.Z.; Prostran, M. Lithium-pharmacological and toxicological aspects: The current state of the art. *Curr. Med. Chem.* 2020, 27, 337–351. [CrossRef]

24. Timmer, R.T.; Sands, J.M. Lithium intoxication. *J. Am. Soc. Nephrol.* 1999, 10, 666–674. [CrossRef]

25. Mehta, R.L.; Kellum, J.A.; Shah, S.V.; Molitoris, B.A.; Ronco, C.; Warnock, D.G.; Levin, A.; Injury, N.A.K. Acute kidney injury network: Report of an initiative to improve outcomes in acute kidney injury. *Crit. Care 2007*, 11, R31. [CrossRef]

26. Azab, A.N.; Shnaider, A.; Osher, Y.; Wang, D.; Bersudsky, Y.; Belmaker, R.H. Lithium nephrotoxicity. *Int. J. Bipolar. Disord.* 2015, 3, 28. [CrossRef]

27. Kansagra, A.J.; Yang, E.; Namibiar, S.; Patel, P.S.; Karetzky, M.S. A rare case of acute respiratory distress syndrome secondary to acute lithium intoxication. *Am. J. Ther.* 2014, 21, e31–e34. [CrossRef] [PubMed]

28. Raja, M. Lithium and kidney, 60 years later. *Curr. Drug. Saf.* 2011, 6, 291–303. [CrossRef]

29. Friedman, B.C.; Bekes, C.E.; Scott, W.E.; Bartter, T. Ards following acute lithium carbonate intoxication. *Intensive Care Med.* 1992, 18, 123–124. [CrossRef]

30. Lawler, P.G.; Cove-Smith, J.R. Acute respiratory failure following lithium intoxication. A report of two cases. *Anaesthesia* 1986, 41, 623–627. [CrossRef]

31. Bloomfield, F.J.; Young, M.M. Influence of lithium and fluoride on degranulation from human neutrophils in vitro. *Inflammation* 1982, 6, 257–267. [CrossRef] [PubMed]

32. Weiner, M.; Chausow, A.; Wolpert, E.; Addington, W.; Szidon, P. Effect of lithium on the responses to added respiratory resistances. *N. Engl. J. Med.* 1983, 308, 319–322. [CrossRef] [PubMed]

33. Crossley, N.A.; Bauer, M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: Two meta-analyses of randomized, placebo-controlled trials. *J. Clin. Psychiatry* 2007, 68, 935–940. [CrossRef]

34. Bschor, T. Lithium in the treatment of major depressive disorder. *Drugs* 2014, 74, 855–862. [CrossRef] [PubMed]

35. Alda, M. Lithium in the treatment of bipolar disorder: Pharmacology and pharmacogenetics. *Mol. Psychiatry* 2015, 20, 661–670. [CrossRef]